Alessandro Santin MD

Obstetrics & Gynecology•New Haven, CT

Professor, Obstetrics & Gynecology, Yale University School of Medicine

Join to View Full Profile

20 York StNew Haven, CT 06510
Phone+1 203-737-4450
Fax+1 203-737-4339

Summary

Dr. Alessandro Santin is an Obstetrics & Gynecology specialist based in New Haven, CT. He completed his medical education and Residency in OB/GYN at the University of Brescia, Italy, in 1989 and 1993, respectively. He completed a research fellowship in Gynecologic Oncology & Immunology at the University of California (UCI), Irvine and a clinical/surgical gynecologic oncology fellowship at University of Arkansas for Medical Sciences (UAMS). His areas of expertise include ovarian, uterine and cervical neoplasms, targeted therapeutics, and immunotherapy. He has authored over 300 publications in peer reviewed medical journals on topics related to the Gynecologic Oncology subspecialty. Dr. Santin clinical trials have significantly impacted the standard of care for women with ovarian and endometrial cancer. He has been listed as America's Top Doctors and America's Top Doctors for Cancer by Castle Connolly from 2009 to 2025.

Education & Training

Yale School of MedicineClass of 1989

Certifications & Licensure

AR State Medical License 1998 - 2026
CT State Medical License 2007 - 2025

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2010-2014
Top Doctors: New York Metro Area Castle Connolly, 2010-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
America's Top Doctors for Cancer Castle Connolly, 2009-2013
Join now to see all

Clinical Trials

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer Start of enrollment: 2011 Jun 01
Completed
Phase 2
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer Start of enrollment: 2015 May 18
ACTIVE_NOT_RECRUITING
PHASE2
A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma
RECRUITING
PHASE2
Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer Start of enrollment: 2016 Sep 16
Completed
Phase 2
Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab Start of enrollment: 2017 Apr 03
Completed
Phase 2
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer Start of enrollment: 2020 Jul 15
RECRUITING
PHASE2
A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma Start of enrollment: 2020 Mar 17
RECRUITING
PHASE2
Roles: Contact, Principal Investigator, Sponsor-Investigator
Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3) Start of enrollment: 2016 Jul 01
Completed
Phase 2
Roles: Contact, Principal Investigator
A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients Start of enrollment: 2024 Jan 08
RECRUITING
PHASE2
Roles: Principal Investigator, Sponsor-Investigator, Contact
A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer Start of enrollment: 2023 Jun 02
RECRUITING
PHASE2
Roles: Sponsor-Investigator, Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

1 citations
Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma.
Daniela E Matei, Danielle M Enserro, Marcus E Randall, David Mutch, William Small
Journal of Clinical Oncology. 2025-03-20
1 citations
Targetable ERBB2/HER2 Mutations in Gynecologic Malignancies: Clinicopathological, Immunohistochemical, and Molecular Correlations.
Padmini A Manrai, Austin McHenry, Tong Sun, Alessandro D Santin, Elena Ratner
International Journal of Gynecological Pathology. 2025-03-01
1 citations
N-acetylcysteine (NAC) supplementation improves dyspnea and may normalize von Willebrand plasma levels in gynecologic patients with Post-Acute-COVID-Sequela (PASC)/Lon...
Stefania Bellone, Eric R Siegel, Alessandro D Santin
Gynecologic Oncology Reports. 2025-02-01

Journal Articles

Phase II Evaluation of Nivolumab in the Treatment of Persistent or Recurrent Cervical Cancer (NCT02257528/NRG-GY002)
Alessandro D Santin, Michael Frumovitz, Natalia Buza, Samir Khleif, Elena S Ratner, Roisin E O'Cearbhaill, Michael Birrer, Gynecologic Oncology

Lectures

A phase II evaluation of nivolumab, a fully human antibody against PD-1, in the treatment of persistent or recurrent cervical cancer.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Sacituzumab Govitecan Shows Promise in Advanced Endometrial CancerAugust 15th, 2024
2023 ‘Top Doctors’ List Features Over 250 Yale Medicine PhysiciansMay 3rd, 2023
Connecticut Magazine’s 2023 “Top Doctors” Issue Recognizes 82 Smilow Cancer Hospital and Yale Cancer Center PhysiciansMay 1st, 2023
Join now to see all